Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious Puberty

NCT06129539 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT06129539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06129539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious Puberty
Lead sponsor
Debiopharm International SA
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 31, 2024
Completion date
February 29, 2028
Enrollment
56 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

central precocious puberty